In part one of our deep dive into the business and financing developments in the emerging and exciting field of immune-oncology, we focused on the red hot partnering activity that is taking place. This article looks at some representative deals from the investment capital flowing into early stage companies. (See BioWorld Insight, May 31, 2016.) Read More
